Publications by authors named "N Mewton"
Ventricular fibrillation (VF)-induced cardiac arrest frequently complicates ST-segment elevation myocardial infarction (STEMI). Although larger infarct sizes (IS) correlate with a higher risk of VF, the influence of VF itself on IS has remained poorly investigated. To address this knowledge gap, we analyzed the effect of VF on IS in patients and two experimental models.
View Article and Find Full Text PDFArticle Synopsis
- Cardiac amyloidosis (CA) is an often overlooked cause of heart failure (HF), highlighting the importance of early detection and timely therapy for better patient outcomes.
- A global survey with 1,460 physicians revealed that while many have experience diagnosing CA in patients with preserved ejection fraction (HFpEF), systematic screening is not widely practiced, with only 10% conducting routine checks.
- There is significant variability in screening and management strategies for CA, indicating a need for better education and access to disease-modifying therapies within the HF community.
Article Synopsis
- Guidelines suggest low-dose colchicine can help prevent secondary cardiovascular issues, but its effectiveness for stroke and safety risks are still uncertain.
- A meta-analysis of six trials with nearly 15,000 patients showed colchicine reduces the risk of ischaemic stroke and major cardiovascular events by 27% without increasing serious safety concerns.
- Colchicine's benefits were consistent across different patient groups, and it didn't raise the risk of hospitalization for serious conditions or all-cause mortality.
Article Synopsis
- This study evaluates global differences in the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF) through an international survey of 1459 physicians, including both cardiologists and non-cardiologists.
- The survey revealed significant regional variations in HFpEF management, such as differences in natriuretic peptide usage and echocardiographic practices, with cardiologists managing the majority of HFpEF patients.
- The preferred treatment methods varied by region, with sodium glucose co-transporter-2 inhibitors (SGLT2i) being the most favored first-line treatment, though availability of these drugs differs significantly across locations.